![]() Thus, the proposed study defines the challenges for developing a suitable formulation system overcoming the delivery barriers of the vaginal site. ![]() A remarkable decrease in CFUs was also observed in comparison with control and marketed formulation when evaluated in rat infection model. When evaluated in vivo, it did not exhibit any irritation potential despite appreciable bioadhesion. ![]() MTT assay did not show any cytotoxic effect of the gel. Optimized gel exhibited a desired gelling temperature (35 ☌) viscosity (0.920 PaS) and appreciable in vitro drug release (62.2% in 20 h). ![]() Carbopol 934 and Pluronic F 127 were taken for the development of gel. Stearic acid and Compritol 888 (1:1, w/w ratio) as lipid, a mixture of 3% Poloxomer 188 and 0.5% sodium taurocholate as surfactant and organic to aqueous ratio of 10:50 was taken. Optimized SLNs with the given composition was selected for further development into mucoadhesive and thermosensitive gel. Keeping in view this attribute of the target site, the current work was aimed at developing formulation strategies which could overcome this and successfully deliver molecules like itraconazole through SLNs. Efficient drug delivery at vaginal cavity is often a challenge owing to its peculiar physiological variations including vast differences in pH.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |